Five-Year Outcomes of Patients With Mitral Structural Valve Deterioration Treated With Transcatheter Valve in Valve Implantation – A Single Center Prospective Registry

Nili Schamroth Pravda1*, Raffael Mishaev2, Amos Levi1, Guy Witberg1, Yaron Shapira1, Katia Orvin1, Yeela Talmor Barkan1, Ashraf Hamdan1, Ram Sharoni3, Leor Perl1, Alexander Sagie1, Hana Vaknin Assa1, Ran Kornowski1 and Pablo Codner1

1Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel associated with Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3Cardio-Thoracic Surgery Department, Faculty of Medicine, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel

The Valve-in-Valve (ViV) technique is an emerging alternative for the treatment of bioprosthetic structural valve deterioration (SVD) in the mitral position. We report on intermediate-term outcomes of patients with symptomatic SVD in the mitral position who were treated by transcatheter mitral valve-in-valve (TM-ViV) implantation during the years 2010–2019 in our center. Three main outcomes were examined during the follow-up period: NYHA functional class, TM-ViV hemodynamic data per echocardiography, and mortality. Our cohort consisted of 49 patients (mean age 77.4 ± 10.5 years, 65.3% female). The indications for TM-ViV were mainly for regurgitant pathology (77.6%). All 49 patients were treated with a balloon-expandable device. The procedure was performed via transapical access in 17 cases (34.7%) and transfemoral vein/trans-atrial septal puncture in 32 cases (65.3%). Mean follow-up was 4.4 ± 2.0 years. 98% and 91% of patients were in NYHA I/II at 1 and 5 years, respectively. Mitral regurgitation was ≥moderate in 86.3% of patients prior to the procedure and this decreased to 0% (p < 0.001) following the procedure and was maintained over 2 years follow-up. The mean trans-mitral valve gradients decreased from pre-procedural values of 10.1 ± 5.1 mmHg to 7.0 ± 2.4 mmHg at 1 month following the procedure (p = 0.03). Mortality at 1 year was 16% (95%, CI 5–26) and 35% (95%, CI 18–49) at 5 years. ViV in the mitral position offers an effective and durable treatment option for patients with SVD at high surgical risk.

Keywords: mitral valve, structural valve deterioration, valve-in-valve, transcatheter, outcomes

INTRODUCTION

Bioprosthetic surgical valve replacement for the treatment of native valve disease has increased over the last two decades, resulting in an increased number of patients presenting with structural valve deterioration (SVD). The treatment of failed bioprosthetic valves has traditionally been surgical valve replacement. However, in those at increased surgical risk, reoperation has
associated substantial morbidity and mortality (1, 2). Transcatheter mitral valve-in-valve (TM-ViV) implantation inside failed surgically implanted bio-prostheses is an increasingly used, less invasive, alternative to repeat surgery in high-risk patients (3, 4). We report on our clinical experience of treating patients in the mitral position using the ViV technique in our institution, aiming to provide insights into the intermediate-term clinical outcomes of these patients.

MATERIALS AND METHODS

The characteristics and outcomes of patients with bioprosthetic SVD treated by the implantation of a TM-ViV device within a failed surgical valve are described in the present report. A cohort included patients undergoing TM-ViV procedures performed from October 2010 to October 2019. Patient data follow-up was completed until November 2021. Operative risk was determined by the logistic European System for Cardiac Operative Risk Evaluation score (log EUROSCORE) and the Society of Thoracic Surgeons (STS) score (5, 6). All patients were discussed in the setting of local Heart Team with interventionalist and imaging cardiologists and cardiothoracic surgeon with experience in mitral valve surgery. All patients underwent transthoracic and transesophageal (TEE) echocardiogram. The baseline, procedural and peri-procedural findings are described. The prospective data collection was approved by the institutional review board. Three endpoints were examined: NYHA (New York Heath Association) functional status at 1- and 5-year, valve hemodynamic of the implanted valves as per echocardiography done at 1 month after the procedure and yearly thereafter and rates of survival during the follow-up period.

Data on mortality was based on mortality files derived from the notification of death form legally required by the Ministry of the Interior. Subgroup analysis was done comparing mortality of those undergoing the procedure transapically vs. trans atrial-septal approach. Follow-up data were available for 42 patients at 1-year follow-up and 11 patients at 5-year follow-up.

Baseline characteristics of the patients are presented as mean and standard deviation (SD) for continuous variables and count (%) for categorical variables. Continuous variables were compared using the Student’s t-test/Mann–Whitney U test, categorical variables were compared using the chi-square/Fisher’s exact test, as appropriate. All tests were 2 tailed, and a p-value <0.05 was considered significant. All-cause mortality was graphically plotted using Kaplan–Meier curves and compared between groups using the log rank test (unadjusted analysis). All TM-ViV-related data was registered in an electronic file and analyzed using the SPSS, version 25.0, software (SPSS, Chicago, IL, United States).

RESULTS

The baseline clinical and echocardiographic characteristics of the cohort are shown in Tables 1, 2. The cohort consisted of 49 patients with a mean age of 77.4 ± 10.5 years, female 65.3%. The mean STS score was 7.7 ± 6.5 and most patients (78%) were in NYHA (New York Heart Association) functional class III/IV at baseline. The average time to TM-ViV from surgical mitral valve replacement was 11.3 ± 3.7 years. The indication for TM-ViV was predominantly for regurgitant pathology (77.6%). Most patients (95.9%) had normal left ventricular function (Ejection Fraction ≥50%) at baseline. Average follow up was 4.4 ± 2.0 years following the procedure.

| TABLE 1 | Baseline characteristics of the cohort. |
|-----------------|---------------------------------|
| TM-ViV           | N = 49 (%)                      |
| Age (years)     | 77.4 ± 10.5                     |
| Male (%)        | 17 (34.7)                       |
| BMI (kg/m²)     | 27.1 ± 5.1                      |
| STS score       | 7.7 ± 6.5                       |
| Euroscore II    | 8.9 ± 4.3                       |
| Coronary artery disease (%) | 16 (32.7) |
| Prior coronary artery bypass surgery (%) | 14 (28.0) |
| Prior PCI (%)   | 5 (10.2)                        |
| Prior CVA/TIA (%) | 7 (14.6)               |
| Peripheral vascular disease (%) | 4 (8.2) |
| Diabetes mellitus (%) | 11 (22.9)                  |
| Hypertension (%) | 42 (87.5)                      |
| Chronic dialysis (%) | 1 (2.0)                        |
| Chronic obstructive pulmonary disease (%) | 12 (24.5)            |
| Atrial fibrillation/flutter (%) | 34 (69.4)                  |
| NYHA functional class III/IV (%) | 36 (75.0)                 |
| Permanent pacemaker/defibrillator (%) | 5 (10.2)                     |
| Hemoglobin (g/dL) | 11.5 ± 1.7                  |
| GFR (MDRD) (mL/Mn²) | 55.9 ± 26.8              |
| Albumin (g/dL)  | 3.9 ± 0.5                       |

| TABLE 2 | Baseline echocardiographic characteristics. |
|-----------------|---------------------------------|
| TM-ViV           | N = 49 (%)                      |
| Valve pathology |                                |
| Stenosis (%)    | 7 (14.3)                        |
| Regurgitation (%)| 38 (77.6)                      |
| Combined (%)    | 4 (8.2)                         |
| Peak gradient (mmHg) | 20.7 ± 9.0              |
| Mean gradient (mmHg) | 10.1 ± 5.1                  |
| LVEF (%) (<50%) | 47 (95.9)                      |
| Mean systolic pulmonary artery pressure (mmHg) | 50 mmHg (IQR 47.5,75) |

| Size of valve treated (mm) | 25 | 5 (10.2) |
|                           | 27 | 24 (48.9) |
|                           | 29 | 10 (20.4) |
|                           | 31 | 8 (16.3)  |
|                           | 33 | 2 (4.0)   |

TM-ViV, Transcatheter Mitral Valve-in-Valve; LVEF = Left Ventricular Ejection Fraction.
Procedural Characteristics

Procedural characteristics are shown in Table 3. From October 2010 to January 2017 the procedures were performed via transapical access (17 cases, 34.7%). From January 2017 onward, procedures were done via a transfemoral vein and trans-atrial septal puncture (32 cases, 65.3%). All 49 patients were treated with Sapien XT™ (n = 17) or Sapien™ 3 (n = 32) (Edwards Lifesciences, Irvine, CA, United States), balloon-expandable, transcatheter heart valves. All cases were performed under intra-procedural TEE guidance to assist during trans-atrial septal puncture, assess valve hemodynamics, left ventricular outflow tract (LVOT) obstruction and to assess for significant shunt throughout the iatrogenic atrial septal defect. There were 4 cases in which an iatrogenic atrial septal defect from transeptal balloon septostomy was closed following the TM-VIV procedure, 3 of which were done during the index procedure. There were no cases of acute LVOT obstruction in our cohort. The average hospital stay was 4.8 days. There were no events of periprocedural strokes. There were 2 patients who needed post-procedural permanent pacemaker insertion. The list of bioprosthetic valves type and size and their corresponding transcatheter valve device is shown in appendix (Supplementary Table 1).

Functional Status

As shown in Figure 1 at 1 year, data was available for 41 patients, of which 98% (n = 40) were in NYHA functional class I/II at 1 year. At 5-year follow up, data was available for 11 patients of which 91% (n = 10) were in NYHA I/II.

Hemodynamic Parameters

The temporal changes in hemodynamic indexes were assessed by echocardiography. As shown in Figure 2, mitral regurgitation was ≥moderate in 85.6% of patients prior to the procedure and this decreased to 0% (P < 0.001) following the procedure (1 month) and was maintained over 5 years follow up. The mean peak and mean trans-mitral valve gradients decreased from pre-procedural values of 20.7 ± 9.0 mmHg and 10.1 ± 5.1 mmHg, respectively, to 15.8 ± 5.4 and 7.0 ± 2.4 mmHg at 1 month following the procedure, respectively, p = 0.03 (Figure 3). The values for peak and mean mitral valve gradient remained reduced during the follow up period. Systolic Pulmonary artery pressures decreased from 50 mmHg (IQR 47.5,75) to 47 mmHg (IQR35.5,58) at 1 month follow up, p = 0.016 (Supplementary Figure 1). Tricuspid regurgitation was ≥moderate in 41% of the cohort prior to the procedure and this did not decrease significantly following the procedure (Supplementary Figure 2).

Mortality and Major Complications

Mortality at 1 year and at 5 years was 16% (95% CI 5–26) and 35% (95% CI 18–49), respectively (Figure 4). In a sub-group analysis, there were no differences in mortality between patients that underwent the procedure via transapical or transfemoral/transseptal access (Supplementary Figure 3). There were 3 events of in-hospital death. The first was in a patient who had a concomitant percutaneous mitral paravalvular leak closure using an Amplatz device. This patient's hospitalization was complicated by severe hemolysis, acute-on-chronic kidney injury, sepsis, and ultimate demise. The second patient died from myocardial rupture during TM-VIV insertion, consequent tamponade, and death. The third was a case of hemorrhagic shock due to vascular complications during the procedure. There were two cases of infective endocarditis, both more than 1 year following the procedure [methicillin-sensitive Staphylococcus aureus (MSSA) and coagulate-negative staphylococci (CONS)] and one case of an ischemic stroke in a patient 3 months following the procedure who had concomitant atrial fibrillation.

DISCUSSION

The main objective of our study was to report on the intermediate-term clinical outcomes of patients with SVD treated with TM-VIV from our all-comer single center experience.

Our findings from this retrospective study demonstrated the following: firstly, the functional NYHA status of vast majority of the cohort significantly improved following TM-VIV and this clinical improvement was maintained at follow-up. Secondly, the transvalvular gradients and hemodynamic response to the procedure were favorable among patients and maintained over the duration of the follow-up period. Lastly, and most importantly, all-cause mortality at 1-year and 5-year follow-ups were relatively low, with mortality rates of 16% (95% CI 5–26) and 35% (95% CI 18–49), respectively.

Our findings are congruent with previous reports showing significant improvement in functional status following TM-VIV implantation (4, 7). Okob et al. reported that 80% of surviving patients were at NYHA I/II at 30-day and 1 year follow-up. While these results show an overall high success rate, we expand on these findings showing 98% of surviving patients were at NYHA I/II at 1-year. Moreover, the improvement in functional status was maintained at 5-year follow-up in 91%
FIGURE 1 | NYHA functional class during follow up.

|          | Baseline | 1 Year | 5 Year |
|----------|----------|--------|--------|
| NYHA 4   | 8        | 0      | 0      |
| NYHA 3   | 27       | 1      | 1      |
| NYHA 2   | 12       | 16     | 5      |
| NYHA 1   | 0        | 24     | 5      |

FIGURE 2 | Degree of mitral regurgitation during follow up.
of surviving patients. Our analysis of valve hemodynamics by echocardiography were consistent with previously reported studies (8, 9). Mitral regurgitation (MR) severity post-procedure decreased significantly from 86.3 to 0% ($p < 0.001$) and this was maintained over follow-up. The mean peak and mean trans-mitral valve gradients decreased significantly following the procedure but remained mildly elevated – however, this did not hinder clinical improvement as reflected by the marked improvement in NYHA functional class. Whisenant et al. reported similar findings in their cohort, with a marked improved in functional status even though the mean mitral valve gradients were on average $7.3 \pm 2.73$ mmHg at 30 days follow up (10). The TM-ViV procedure adds a valve into the already limited effective orifice area of the previous mitral valve bioprosthesis and there remains an element of mitral stenosis secondary to the procedure which can explain the valve hemodynamics. The pulmonary artery pressures did not decrease significantly – the pulmonary hypertension secondary to mitral valve disease can often be irreversible due to its chronicity and structural changes in the pulmonary vasculature itself and remain elevated despite an adequate structural intervention (11).

It is important to note that while the valve hemodynamics improved significantly, there was a lack of improvement in those with concomitant tricuspid regurgitation. Secondary tricuspid regurgitation and pulmonary pressures can be irreversible following the procedure.

In our study, the mortality rates at 1 and 5 years were 16 and 35%, respectively. Whisenant et al. reported in 2020 in their large study of 1,529 patients that their 1-year mortality rate was 16.7% (10). These improvements in clinical outcomes reflects a better case selection process, increased operator experience and a refinement of the procedural technique over the years (9, 10). Although in our sub-group analysis there were no differences in mortality between patients that underwent the procedure via transapical or transfemoral/transapical access, Whisenant et al. reported a lower 1-year all-cause mortality in patients treated transeptally vs. transapically (15.8% vs. 21.7%, $P = 0.03$) (10). Zubarevich et al. report 1-year and 3-year mortalities of 28 and 37%, respectively in patients treated solely with transapical access (3). These differences may be explained by the fact that transeptal procedures are minimally invasive and therefore avoid thoracic surgical interventions, leading to faster patient recovery, less peri-procedural complications, and shorter hospital stays. Our findings should be interpreted with caution as our cohort was small.

Transcatheter mitral valve-in-valve procedures via transeptal access require puncture through the atrial septum, and inter-atrial balloon septostomy, leading to iatrogenic atrial
septal defects (iASDs) which can often have hemodynamic consequences (12). There are currently no guidelines as to which iASDs should be closed and therefore necessitates the need for more research. iASD can be advantageous in patients with elevation left atrial pressure as they allow pressure unloading via a left to right shunt. In our series, there were 4 cases of TM-ViV that underwent subsequent iASD closure. These cases were performed as the iASD shunt was deemed significant clinically, mainly due right-to-left shunt, causing systemic hypoxemia.

There is increasing evidence that the percutaneous route may be advantageous over repeat mitral valve surgery. Khan et al. recently published a retrospective comparison between patients undergoing TM-ViV and re-do surgery (13). They found that TM-ViV was associated with a significantly better survival, significantly less periprocedural complications, shorter hospital stays and cost. This was despite the older age and higher burden of comorbidities amongst those undergoing TM-ViV. This advantageous slant to TM-ViV is most likely multifactorial. A pivot factor is that with TM-ViV, the valve in placed within the existing frame of the previous bioprosthesis. While with surgery, the tissue within the mitral valve apparatus is manipulated and this can negatively affect left ventricular function (14, 15).redo surgical mitral valve replacement carries significant morbidity and mortality (9). However, more data is needed regarding the durability and long-term outcomes of redo surgery vs. TM-ViV. TM-ViV has emerged as a relatively safe and effective treatment for patients suffering from SVD. However, unlike for aortic valve replacement treatment, there are no homogenous criteria and guidelines to report outcomes for research purposes. The Valve Academic Research Consortium (VARC) was founded to standardize definitions of outcomes and endpoints after aortic valve replacement, leading to the rapid development of novel therapies and advancements in clinical research (16). There is an increasing need for standardized criteria for TM-ViV, yet no such consortium exists for mitral valve replacements. Furthermore, randomized control studies of larger cohorts are necessary to validates our findings of safety, efficacy, and durability of TM-ViV implantations.

As the number of patients undergoing TM-ViV increases, so does the incidence of post-procedural complications. The concept of neo LVOT obstruction has been documented in previous reports of TM-ViV complications (10, 17). The use of preprocedural computed tomography (CT) imaging has been shown to be essential in the prevention of this complications (17). We reported no cases of

![Figure 4: Mortality during follow up.](image-url)
significant LVOT obstruction in our study. CT has become a routine imaging tool in the pre-procedure assessment of our patients. The risk of LVOT obstruction in our patient population was assessed and discussed with careful analysis of the available imaging using predicted LVOT measurement, assessing the length of the prosthetic surgical valve leaflets, measuring the dimensions of the LVOT, assessing for bulging intraventricular septum and planning the TM-ViV height of implantation accordingly.

The main strengths of our study are the quality of our data acquisition and the intermediate-term follow-up. We are a center with a dedicated structural intervention team with increasing experience and data spanning almost 10 years. We have a dedicated data collection team and structured clinical and imaging follow-up program to ensure careful data acquisition and quality. The TM-ViV procedure offers a safe, feasible, less invasive, and long-lasting solution to structural valve deterioration. We report longer follow-ups than previous papers and show an increase in functional status, improvement in structural hemodynamics, and decrease in mortality 5-years post-procedure.

Study limitations are that this is a single-center retrospective analysis and a relatively small cohort. There is inherent selection bias of our cohort as all patients underwent a thorough assessment process as candidates for this procedure. This is evident as the average STS score was intermediate (and not very high-risk) and that most patients had left ventricular ejection fraction about 50%. These factors may partially explain our encouraging outcomes.

CONCLUSION

Transcatheter mitral valve-in-valve for the treatment of SVD yielded encouraging results in safety and efficiency in our single-center experience. Our cohort had significant clinical and hemodynamical improvement with promising intermediate-term results. TM-ViV is an emerging treatment option for SVD in the mitral position.

REFERENCES

1. Fatehi Hassanabad A, Turcotte M, Denneyh C, Kim A, Malaisrie SC, Kent WDT. Contemporary reoperative mitral valve surgery: technical considerations and clinical outcomes. Innovations. (2020) 15:425–39. doi: 10.1177/1556985220949955
2. Jones JM, O’Kane H, Gladstone DJ, Sarsam MA, Campalani G, MacGowan SW, et al. Repeat heart valve surgery: risk factors for operative mortality. J Thorac Cardiovasc Surg. (2001) 122:913–8. doi: 10.1067/mtc.2001.116470
3. Zubarevich A, Szczecichowicz M, Zhigalov K, Marx P, Lind A, Jánosi RA, et al. Transapical transcatheter mitral valve implantation in patients with degenerated mitral bioprostheses or failed ring annuloplasty. Ann Cardiotoracic Surg. (2021) 10:674–82. doi: 10.21037/acs-2021-tvivs-67
4. Okoh AK, Shah A, Kang N, Almaz B, Resnick J, Ghaffar A, et al. Outcomes after transcatheter mitral valve-in-valve replacement in patients with degenerated bioprostheses: a single-center experience. J Invasive Cardiol. (2020) 32:49–54.
5. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothoracic Surg. (1999) 16:9–13. doi: 10.1016/s1010-7949(99)00134-7
6. Shahian DM, O’Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. Society of thoracic surgeons quality measurement task force. The society of thoracic surgeons 2008 cardiac surgery risk models: part 1–coronary artery bypass grafting surgery. Ann Thorac Surg. (2009) 88:S2–22. doi: 10.1016/j.athorsur.2009.05.053
7. Arnold SV, Li Z, Vemulapalli S, Baron SJ, Mack MJ, Kosinski AS, et al. Association of transcatheter mitral valve repair with quality of life outcomes at 30 days and 1 year: analysis of the transcatheter valve therapy registry. JAMA Cardiol. (2018) 3:1151–9. doi: 10.1001/jamacardio.2018.33359
8. Simonato M, Whisenant B, Ribeiro HB, Webb JG, Kornowski R, Guerrero M, et al. Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID registry. Circulation. (2021) 143:104–16. doi: 10.1161/CIRCULATIONAHA.120.049088
9. Sarkar K, Reardon MJ, Little SH, Barker CM, Kleiman NS. Transcatheter mitral valve replacement for native and failed bioprosthetic mitral valves. Methodist Debakey Cardiovasc J. (2017) 13:142–51. doi: 10.14797/mdcj-13-3-142
10. Whisenant B, Kapadia SR, Edele MF, Kodali SK, McCabe JM, Krishnaswamy A, et al. One-year outcomes of mitral valve-in-valve using the SAPIEN 3

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Helsinki Ethics Committee Rabin Medical Center. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

AUTHOR CONTRIBUTIONS

All authors contributed substantial contributions to the conception or design of the work, or the acquisition, analysis or interpretation of data for the work, including drafting the work or revising it critically for important intellectual content, provide approval for publication of the content, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

SUPPLEMENTARY MATERIAL

The original Contributions for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm. 2022.883242/full#supplementary-material

Supplementary Figure 1 | Systolic pulmonary artery pressures during follow up.
Supplementary Figure 2 | Degree of tricuspid regurgitation during follow up.
Supplementary Figure 3 | Mortality as per transapical vs. transvenous/transeptal approach.
transcatheter heart valve. *JAMA Cardiol.* (2020) 5:1245–52. doi: 10.1001/jamacardio.2020.2974

11. Hahn RT, Asch F, Weissman NJ, Grayburn P, Kar S, Lim S, et al. Impact of tricuspid regurgitation on clinical outcomes: the COAPT trial. *J Am Coll Cardiol.* (2020) 76:1305–14. doi: 10.1016/j.jacc.2020.07.035

12. Beri N, Singh GD, Smith TW, Fan D, Boyd WD, Rogers JH. Iatrogenic atrial septal defect closure after transseptal mitral valve interventions: indications and outcomes. *Catheter Cardiovasc Interv.* (2019) 94:829–36. doi: 10.1002/ccd.28294

13. Khan MZ, Zahid S, Khan MU, Kichloo A, Jamal S, Minhas AMK, et al. Redo surgical mitral valve replacement versus transcatheter mitral valve in valve from the national inpatient sample. *J Am Heart Assoc.* (2021) 10:e020948. doi: 10.1161/JAHA.121.020948

14. Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. *Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine.* 10th ed. Philadelphia, PA: Elsevier/Saunders (2015).

15. Glower DD. Surgical approaches to mitral regurgitation. *J Am Coll Cardiol.* (2012) 60:1315–22. doi: 10.1016/j.jacc.2011.11.081

16. Varc-3 Writing Committee, Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. *J Am Coll Cardiol.* (2021) 77:2717–46. doi: 10.1016/j.jacc.2021.02.038

17. Ben Zekry S, Turaga M, Tarazi S, Bax JJ, Wang DD, Piazza N, et al. Neo-LVOT and transcatheter mitral valve replacement: expert recommendations. *JACC Cardiovasc Imaging.* (2021) 14:854–66. doi: 10.1016/j.jcmg.2020.09.027

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Schamroth Pravda, Mishaei, Levi, Wöbbe, Shapiro, Orvin, Barkan, Hamdan, Sharoni, Perl, Sagie, Assa, Kornowski and Codner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.